Pfizer axes development of Duchenne muscular dystrophy antibodyPfizer has axed trials of its domagrozumab antibody for Duchenne muscular dystrophy (DMD), after it failed against efficacy Share XPfizer axes development of Duchenne muscular dystrophy antibodyhttps://pharmaphorum.com/news/duchenne-trials-axed-pfizer-dmd/
Pfizer drug reduces mortality in patients with fatal heart diseasePfizer’s heart disease drug, tafamidis, reduces mortality rates in patients, according to the top-line results of a phase Share XPfizer drug reduces mortality in patients with fatal heart diseasehttps://pharmaphorum.com/news/tafamidis-reduces-mortality/
Drug firms fight US government’s Iraq corruption probeUS Department of Justice investigating J&J, Pfizer, Roche and others Share XDrug firms fight US government’s Iraq corruption probehttps://pharmaphorum.com/news/drug-firms-fight-us-governments-iraq-corruption-probe/
US government may cease prescription rebatesPfizer’s CEO believes the US government will eliminate rebates on prescription drugs. As the company’s second quarter results Share XUS government may cease prescription rebateshttps://pharmaphorum.com/news/pfizers-ceo-believes-us-government-will-eliminate-prescription-rebates/
Pfizer/Lilly non-opioid pain drug hits mark in phase 3 trialAfter years of delays Pfizer and Eli Lilly’s tanezumab non-opioid pain drug is edging closer to approval, after Share XPfizer/Lilly non-opioid pain drug hits mark in phase 3 trialhttps://pharmaphorum.com/news/pfizer-lilly-tanezumab-pain-drug-hits-mark-in-phase-3-trial/
Pfizer backed off, but the price hike game continuesDonald Trump may have convinced the US pharma giant Pfizer to defer a price increase for dozens of Share XPfizer backed off, but the price hike game continueshttps://pharmaphorum.com/news/pfizer-backed-off-but-the-price-hike-game-continues/
Pfizer splits into three after failing to sell consumer unitPfizer has decided to split into three after it failed to sell its consumer healthcare business a few Share XPfizer splits into three after failing to sell consumer unithttps://pharmaphorum.com/news/pfizer-splits-into-three-after-failing-to-sell-consumer-unit/
Pfizer defers drug price hike after Trump phone callPfizer has decided to defer the recent drug price increase after a long discussion with president Trump and Share XPfizer defers drug price hike after Trump phone callhttps://pharmaphorum.com/news/pfizer-defers-drug-price-hike-after-trump-phone-call/
Pfizer increases prices in the US for the second time this yearThe largest standalone drug maker in the US, announced it increase the prices of around 100 drugs for Share XPfizer increases prices in the US for the second time this yearhttps://pharmaphorum.com/news/pfizer-increases-prices-us-second-time/